In glioma, the decrease in EAAT2 (also known as solute carrier family 1 member 2 (SLC1A2) or glutamate transporter 1 (GLT-1)) correlates with tumor malignancy (63), making the potential involvement of EAAT in tumor-associated diseases much more relevant. The gene discussed is SLC1A2; the disease is central nervous system cancer.